Facilitators and Barriers of Incremental Innovation by Fixed Dose Combinations in Cardiovascular Diseases

Autor: András Inotai, Zoltán Kaló, Zsuzsanna Petykó, Kristóf Gyöngyösi, Derek T. O’Keeffe, Marcin Czech, Tamás Ágh

Publikováno v: Journal of Cardiovascular Development and Disease, Vol 11, Iss 7, p 186 (2024)

Despite the availability of affordable pharmaceuticals treating cardiovascular diseases (CVDs), many of the risk factors remain poorly controlled. Fixed-dose combinations (FDCs), a form of incremental innovation, have already demonstrated improvement

Externí odkaz: https://doaj.org/article/843d88aca28848479dac2377566a0dc8

Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives

Autor: Zoltán Kaló, Zsuzsanna Ida Petykó, Frank-Ulrich Fricke, Nikos Maniadakis, Tomáš Tesař, Kateřina Podrazilová, Jaime Espin, András Inotai

Publikováno v: Cost Effectiveness and Resource Allocation, Vol 19, Iss 1, Pp 1-8 (2021)

Abstract Background A core evaluation framework that captures the health care and societal benefits of value added medicines (VAMs, also often called repurposed medicines) was proposed in Report 1, aiming to reduce the heterogeneity in value assessme

Externí odkaz: https://doaj.org/article/21d9cfc512d44c0598b4a76e7a3c05e0

The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future

Autor: Brian Godman, Mainul Haque, Trudy Leong, Eleonora Allocati, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Carlos Vassalo, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M. Muksudul Alam, Iffat Jahan, Zubair Mahmood Kamal, Humaira Hasin, Munzur-E-Murshid, Shamsun Nahar, Monami Haque, Siddhartha Dutta, Jha Pallavi Abhayanand, Rimple Jeet Kaur, Godfrey Mutashambara Rwegerera, Renata Cristina Rezende Macedo do Nascimento, Isabella Piassi Dias Godói, Mohammed Irfan, Adefolarin A. Amu, Patrick Matowa, Joseph Acolatse, Robert Incoom, Israel Abebrese Sefah, Jitendra Acharya, Sylvia Opanga, Lisper Wangeci Njeri, David Kimonge, Hye-Young Kwon, SeungJin Bae, Karen Koh Pek Khuan, Abdullahi Rabiu Abubakar, Ibrahim Haruna Sani, Tanveer Ahmed Khan, Shahzad Hussain, Zikria Saleem, Oliver Ombeva Malande, Thereza Piloya-Were, Rosana Gambogi, Carla Hernandez Ortiz, Luke Alutuli, Aubrey Chichonyi Kalungia, Iris Hoxha, Vanda Marković-Peković, Biljana Tubic, Guenka Petrova, Konstantin Tachkov, Ott Laius, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuoliene, Jolanta Gulbinovič, Magdalene Wladysiuk, Jakub Rutkowski, Ileana Mardare, Jurij Fürst, Stuart McTaggart, Sean MacBride-Stewart, Caridad Pontes, Corinne Zara, Eunice Twumwaa Tagoe, Rita Banzi, Janney Wale, Mihajlo Jakovljevic

Publikováno v: Frontiers in Public Health, Vol 9 (2021)

Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control inclu

Externí odkaz: https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad

Gondolatok a magyar gazdasági stratégia saroktényezőiről a globális válság tükrében

Autor: András Inotai

Publikováno v: Köz-gazdaság, Vol 6, Iss 1 (2020)

A 2008 utolsó negyedében kibontakozott, majd 2009-ben teljes erővel ható globális pénzügyi és makrogazdasági válság alapvető sajátossága, hogy 1945 után gyakorlatilag első alkalommal a fejlett világból indult ki, a második világh�

Externí odkaz: https://doaj.org/article/1fb7fd9b02ca4127b998795e6a6d59ed

Potential Cost-Savings From the Use of the Biosimilars in Slovakia

Autor: Tomas Tesar, Peter Golias, Zuzana Kobliskova, Martin Wawruch, Paweł Kawalec, András Inotai

Publikováno v: Frontiers in Public Health, Vol 8 (2020)

Objectives: To analyse the market shares of biosimilars in Slovakia and to calculate the potential cost-savings from the use of biosimilars in Slovakia based on two different data sources.Methods: National reimbursement lists from the Czech Republic,

Externí odkaz: https://doaj.org/article/775c30d9d4f444669026bebeba0186ce